A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer-Reference-Cited by-同舟云学术

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer

Published:2013-03-24 Issue:5 Volume:71 Page:1141-1146
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Suzuki Eiichiro,Ikeda Masafumi,Okusaka Takuji,Nakamori Shoji,Ohkawa Shinichi,Nagakawa Tatsuya,Boku Narikazu,Yanagimoto Hiroaki,Sato Tosiya,Furuse Junji

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-013-2106-0/fulltext.html

Reference26 articles.

1. Matsuda T, Marugame T (2007) International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from cancer incidence in five continents, vol VIII. Jpn J Clin Oncol 37(1):74–75

2. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20(1):146–159

3. Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13(4):415–423

4. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96(6):896–902

5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial;Journal of Clinical Oncology;2024-08-05

2. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis;Future Oncology;2024-04

3. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study;Journal of Clinical Oncology;2023-12-20

4. Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test;Clinical Case Reports;2023-07

5. Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib;Internal Medicine;2023-04-15